About this raise

Bioverge, with a post-money valuation of $11 million, is raising funds on NetCapital. It is an investment platform that funds entrepreneurs with the aim to transform healthcare. The platform allows both accredited and non-accredited investors to invest in healthcare startups and support them. Neil J. Littman and Rick Gibb founded Bioverge in 2017. The current crowdfunding round has a minimum raise of $10,000 and a maximum raise of $1,069,999, and the funds will be used for product development, sales and marketing, and general and administrative expenses. Bioverge has successfully closed 32 deals across 21 portfolio companies.

Expand

Investment Overview

Invested this round: $710,266

Deal Terms

Total Commitments ($USD)

Platform
Netcapital
Start Date
05/14/2021
Close Date
02/28/2022
Min. Goal
$10,000
Max Goal
$1,069,999
Min. Investment

$99

Security Type

Equity - Common

Series

Pre-Seed

SEC Filing Type

RegCF    Open SEC Filing

Price Per Share

$1.14

Pre-Money Valuation

$10,014,900

Company & Team

Company

Year Founded
2017
Industry
Financial & Insurance Products & Services
Tech Sector
Fintech
Distribution Model
B2B/B2C
Margin
Medium
Capital Intensity
Low
Location
San Francisco, California
Business Type
Growth
Company Website
Visit Website

Team

Employees
2
Prior Founder Exits?
No
Founder Name
Neil Littman
Title
CEO
Founder Name
Rick Gibb
Title
COO

Financials

 Revenue
$68,795
 Monthly Burn
$36,076
 Runway
15.8 months

Summary Profit and Loss Statement

Most Recent Year Prior Year

Revenue

$68,795

$24,047

COGS

$0

$0

Tax

$0

$0

 

 

Net Income

$-432,913

$-161,357

Summary Balance Sheet

Most Recent Year Prior Year

Cash

$570,343

$266,383

Accounts Receivable

$7,034

$4,997

Total Assets

$975,622

$544,624

Short-Term Debt

$123,702

$123,702

Long-Term Debt

$1,363,520

$588,520

Total Liabilities

$1,487,222

$712,222

Create a free account today to gain access to Kingscrowd analytics and financials.

Upgrade to gain access

Pay Monthly
Annually (2 months free)

Edge

$12.50 /month
billed annually
Free portfolio tracking, data-driven ratings, AI analysis and reports
Plan Includes:
Everything in Free, plus
Company specific Kingscrowd ratings and analyst reports
Deal explorer and side-by-side comparison
Startup exit and failure tracking
Startup market filters and historical industry data
Advanced company search ( with ratings)
Get Edge Annual
Already a member? Log in here.

Ratings Kingscrowd Startup Rating Methodology Article

Blurred Ratings Bars Blurred Ratings Bars

Company Funding & Growth

Funding history

Close Date Platform Valuation Total Raised Security Type Status Reg Type
08/07/2023 Republic $25,000,000 $138,007 SAFE Funded RegCF
02/28/2022 Netcapital $10,014,900 $710,266 Equity - Common Funded RegCF
05/13/2021 Netcapital $10,014,900 $0 Equity - Common Funded Test the Waters / RegCF
Create a free account today to gain access to Kingscrowd analytics.

Growth Charts

Revenue History

Note: Revenue data points reflect the latest of either the most recent fiscal year's financials, or updated revenues directly from the founder, at each raise's close date.

Valuation History

Price per Share History

Note: Share prices shown in earlier rounds may not be indicative of any stock splits.

Employee History

Founders: enhance your startup's credibility on Kingscrowd. Create an account to claim this raise page.
Add to portfolio
Bioverge on NetCapital
Platform: Netcapital
Security Type: Equity - Common
Valuation: $10,014,900
Price per Share: $1.14

Follow company

Follow Bioverge on NetCapital

Buy Bioverge's Deal Report

Warning: according to the close date for this deal, Bioverge may no longer be accepting investments.

Bioverge Deal Report

Get Kingscrowd's comprehensive report on Bioverge including:

  • How our proprietary algorithm rates their current capital raise (1-5 stars)
  • Detailed price, market, team, differentiators, performance, and risk ratings
  • Whether Bioverge is undervalued or overvalued
  • Scores on the founding team and key personnel's background and expertise

Buy the Bioverge deal report for only $10!

Email address:
Looking to buy more than one deal report? Get unlimited reports by upgrading to Edge